Skip to main content

Table 2 Peripheral eosinophil reduction post therapy initiation

From: Targeting the IL-5 pathway in eosinophilic asthma: a comparison of mepolizumab to benralizumab in the reduction of peripheral eosinophil counts

Measure Mepolizumab
(n = 36)
Benralizumab
(n = 19)
p-value
Pre-therapy serum eosinophil count, cells/µL, mean (SD) 597.2 (504.5) 521.6 (546.8) 0.3769
Patients with pre-therapy eosinophilia (≥ 500 cells/µL)    0.2730
 Yes, n (%) 21 (58) 8 (42)  
 No, n (%) 15 (42) 11 (58)  
Post-therapy serum eosinophil count, cells/µL, mean (SD) 103.1 (100.0) 0 (0)
Decrease in serum eosinophil count, cells/µL, mean (SD) 494.1 (492.9) 521.6 (546.8) 0.9079
Patients with undetectable eosinophil count post-therapy    < 0.0001
 Yes, n (%) 11 (31) 19 (100)  
 No, n (%) 25 (69) 0 (0)  
Patients with pre-therapy eosinophilia (≥ 500 cells/µL) who have normal eosinophil counts (< 500 cells/µL) post-therapy    -
 Yes, n (%) 21 (100) 8 (100)  
 No, n (%) 0 (0) 0 (0)  
Time from therapy onset to post-therapy serum eosinophil count, days, mean (SD) 280.4 (191.9) 118.7 (62.2) 0.0066